Continuous cell programming devices

Patent metadata

Field	Value
Publication number	US-10328133-B2
Application number	US-86742609-A
Country	US
Kind code	B2
Filing date	Feb 13, 2009
Priority date	Feb 13, 2008
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

Abstract

The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

First claim

What is claimed is:

1. A method of continuous in situ dendritic cell programming, comprising administering to a subject a device comprising
a scaffold polymer selected from the group consisting of poly-lactide-co-glycolide (PLG), alginate, xantham gum, gellan, or emulsan;
a tumor antigen;
a recruitment composition comprising a cytokine, which comprises a granulocyte macrophage colony stimulating factor (GM-CSF) that recruits one or more dendritic cells to temporarily reside within said device; and
a positively charged polyethylenimine (PEI)-condensed toll-like receptor-9 (TLR-9)-activating CpG-ODN which is retained in or on said scaffold polymer,
wherein said device attracts a dendritic cell and enhances uptake of said CpG-ODN into said dendritic cell, thereby continuously stimulating said dendritic cell to induce an immune response, and wherein said PEI condensed CpG-ODN overcomes the trapping effect of the cytokine on said dendritic cell, thereby inducing said dendritic cell to migrate away from said device.

2. The method of claim 1 , wherein said tumor antigen comprises a biopsy tumor cell lysate.

3. The method of claim 1 , wherein said device is administered locally at or near a tumor site.

4. The method of claim 1 , wherein said dendritic cell comprises a plasmacytoid dendritic cell.

5. The method of claim 1 , wherein the scaffold polymer is alginate.

6. The method of claim 1 , wherein the scaffold polymer is PLG.

7. The method of claim 1 , wherein the CpG-ODN is CpG-ODN 1826.

8. The method of claim 1 , wherein the PEI-CpG-ODN is retained in said scaffold polymer.

Assignees

• Mooney David J
• Ali Omar
• Dranoff Glenn
• Harvard College
• Dana Farber Cancer Inst Inc

Inventors

• Mooney David J
• Ali Omar
• Dranoff Glenn

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/55588

  Adjuvants of undefined constitution · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title